Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Larimar Therapeutics, Inc.

NASDAQ: LRMR · Life Sciences · 10 alerts · CIK 1374690

Share price
$3.00Close, Nov 16
Market cap
$314M
Shares outstanding
104.63MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Larimar Therapeutics, Inc. filings on SEC EDGAR ↗

8:33 AM ET 10-Q
Financial Results

Larimar Therapeutics Q3 2026 Results: Net Loss of $31.1M, Loss Narrows

Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $31.1M
7:18 AM ET 8-K
Financial Results

Larimar Therapeutics Financial Results

Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.

“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”

Carole Ben-Maimon, M.D., Chief Executive Officer

“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”

Carole Ben-Maimon, M.D., Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.